FDA flags 10 observations in another Form 483 for a Zydus plant

2024-05-06
FDA flags 10 observations in another Form 483 for a Zydus plant
Preview
来源: FiercePharma
The FDA visited Zydus' plant in Gujarat, India, last month.
Zydus Lifesciences recently received its second Form 483 reprimand from the FDA within the span of one month. In the second write-up, the regulatory agency flagged issues ranging from unqualified employees performing sample collections to improper evaluations of drug batches.
The agency inspected the company’s site in Gujarat, India, between April 15 and April 23, finding ten observations of manufacturing procedural shortfalls. The FDA posted the more recent Form 483 on April 29.
According to the FDA, Zydus’ facility demonstrated inconsistencies with internal investigations, skirted sampling plans and skipped over procedures meant to prevent microbiological contamination of sterile drug products.
Plus, even after an investigation found cross-contamination in rejected batches, other drug lots produced on the same equipment were released to the U.S. without a thorough investigation, the FDA pointed out.
In one example of Zydus' problems with sampling and testing procedures, an employee was reported to be collecting samples despite not actually doing so and instead delegating the task to a staffer who wasn’t qualified, the FDA said.
The FDA also listed its concerns about Zydus' lack of written procedures to ensure products feature the correct strength, purity and quality. The agency further said Zydus' equipment and utensils weren’t regularly cleaned to prevent contamination, among other regulatory concerns.
The latest Form 483 represents the second recent FDA citation for Zydus.
Last month, the agency posted another Form 483 issued after a March inspection of Zydus’ facility in Matoda, India. During that visit, the FDA flagged four observations, including failure to clean and maintain equipment and a lack of procedures to prevent microbiological contamination of sterile products.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。